Pulmonary complications (as defined by study authors, including pneumonia, embolism, reduced pulmonary function, prolonged ventilation, and pleural effusion, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids may leads to lower pulmonary complications (as defined by study authors, including… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Anticoagulant probably leads to lower pulmonary embolism compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Pulmonary embolism · people requiring treatment for acute DVT
1 finding from 1 review
Pulmonary embolism · people requiring treatment for chronic DVT
1 finding from 1 review
Pulmonary embolism · people hospitalised with COVID‐19
It is very uncertain whether anticoagulants changes pulmonary embolism compared with no treatment (very low certainty).
1 finding from 1 review
Pulmonary embolism · people hospitalised with COVID‐19
Higher‐dose anticoagulants probably leads to lower pulmonary embolism compared with lower‐dose anticoagulants (moderate certainty).
1 finding from 1 review
Pulmonary embolism · passengers on a long haul flight (more than 4 hours)
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes pulmonary embolism compared with no prophylaxis (very low certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with vitamin K antagonist (VKA) (very low certainty).
2 findings from 1 review
Intervention not reported
Pulmonary embolism · Patients hospitalised following acute myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Pulmonary embolism · Hospitalised patients1
The intervention may leads to lower pulmonary embolism (low certainty).
1 finding from 1 review
Intervention not reported
Pulmonary embolism · Patients hospitalised for surgical procedures1
The intervention may leads to lower pulmonary embolism (low certainty).
1 finding from 1 review
Pulmonary embolism · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in any Pulmonary embolism compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in pulmonary embolism compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Pulmonary embolism · Post‐menopausal women with pre‐exisiting cardiovascular disease
Hormone therapy showed no clear difference in pulmonary embolism compared with placebo (moderate certainty).
1 finding from 1 review